You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Over expression of Hormone receptors in carcinoma of the breast sues

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Urothelial Carcinoma, Triple Negative Breast Cancer, NSCLC Trial (SBT6290, pembrolizumab)

Withdrawn
  • Urothelial Carcinoma
  • +4 more
  • (no location specified)
Apr 4, 2022

Estrogen Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 Trial in Seattle (procedure, drug,

Terminated
Has Results
  • Estrogen Receptor Positive
  • +2 more
  • Computed Tomography
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 28, 2021

HER2 Negative Breast Cancer Not Immediately Operated Trial (Ribociclib Oral Tablet)

Not yet recruiting
  • HER2 Negative Breast Cancer Not Immediately Operated
  • Ribociclib Oral Tablet
  • (no location specified)
Dec 16, 2022

Pure Florid and Pleomorphic Lobular Carcinoma in Situ of Breast:

Recruiting
  • Pleomorphic Lobular Breast Carcinoma in Situ
  • Breast Florid Lobular Carcinoma in Situ
  • Surgical wide local excision
  • +4 more
  • Padova, Italy
    Istituto Oncologico Veneto IRCCS
Nov 14, 2023

Identify the Number of Eligible Patients for Immunotherapy According to the Epidemiological and Biological Profile in Tunisia

Not yet recruiting
  • Identify the Number of Eligible Patients for Immunotherapy According to the Epidemiological and Biological Profile in Tunisia
  • identify biomarkers
  • (no location specified)
May 13, 2023

Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma

Not yet recruiting
  • Anatomic Stage 0 Breast Cancer AJCC v8
  • +3 more
  • Accelerated Partial Breast Irradiation
  • Duarte, California
    City of Hope Medical Center
Aug 18, 2023

Klotho _ LRP-6 _ Gastric Adenocarcinoma

Not yet recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • Prognostic study
  • (no location specified)
Jan 29, 2023

Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer Trial in London (Palbociclib, Avelumab)

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Manchester, Greater Manchester, United Kingdom
  • +6 more
Jan 5, 2023

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

Recruiting
  • Breast Cancer
  • +2 more
    • Wuhan, Hubei, China
      TongjiHospital
    Sep 12, 2022

    Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United

    Recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +4 more
    • Birmingham, Alabama
    • +12 more
    Nov 9, 2022

    High-Risk Breast Duct Epithelium

    Completed
    • Breast Cancer
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 8, 2023

      Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor Trial in São Paulo (Tamoxifen)

      Active, not recruiting
      • Neuroendocrine Tumors
      • +2 more
      • Tampa, Florida
      • +1 more
      Jan 13, 2023

      Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

      Recruiting
      • Anatomic Stage I Breast Cancer AJCC v8
      • +3 more
      • Best Practice
      • +5 more
      • Ames, Iowa
        Mary Greeley Medical Center
      Jan 24, 2023

      Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma Trial in

      Active, not recruiting
      • Anatomic Stage IIIB Breast Cancer AJCC v8
      • +4 more
      • Pembrolizumab
      • Houston, Texas
        M D Anderson Cancer Center
      Sep 30, 2022

      Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Anastrozole,

      Active, not recruiting
      • Anatomic Stage IV Breast Cancer AJCC v8
      • +6 more
      • Atlanta, Georgia
      • +9 more
      Oct 12, 2022

      Mammographically Dense Breast Trial in United States (Afimoxifene, Laboratory Biomarker Analysis, Placebo)

      Active, not recruiting
      • Mammographically Dense Breast
      • Tampa, Florida
      • +4 more
      Dec 27, 2022

      Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ Trial in United States (Acolbifene Hydrochloride,

      Not yet recruiting
      • Breast Atypical Hyperplasia
      • +3 more
      • Acolbifene Hydrochloride
      • +4 more
      • Duarte, California
      • +3 more
      Jul 11, 2023

      Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)

      Recruiting
      • Breast Cancer
      • Chidamide Plus Toripalimab Plus Paclitaxel
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Feb 19, 2023

      Metastatic Breast Cancer Trial in Angers, Brest, Saint-Herblain (FES PET/CT)

      Recruiting
      • Metastatic Breast Cancer
      • FES PET/CT
      • Angers, France
      • +2 more
      Aug 24, 2021

      Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

      Not yet recruiting
      • Anatomic Stage II Breast Cancer AJCC v8
      • +3 more
      • Biospecimen Collection
      • +7 more
      • Portland, Oregon
        SWOG
      Sep 27, 2023

      Breast Cancer Trial in Amsterdam (anthracycline-based, docetaxel and capecitabine, tamoxifen)

      Completed
      • Breast Cancer
      • Amsterdam, Netherlands
        Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
      Nov 16, 2022

      Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy

      Recruiting
      • Advanced Breast Cancer
      • The combination of Dalpiciclib with physician-selected endocrine therapy
      • Chemotherapy selected by the physician
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      May 22, 2023

      Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

      Active, not recruiting
      • Estrogen Receptor-positive Breast Cancer
      • +5 more
      • PI3K inhibitor BYL719
      • +3 more
      • Boston, Massachusetts
      • +1 more
      Oct 14, 2022

      Bladder Cancer Trial in Indianapolis, Baltimore, Rockledge (Dovitinib)

      Terminated
      Has Results
      • Bladder Cancer
      • Indianapolis, Indiana
      • +2 more
      Jul 7, 2022

      Cancer Trial in St. Gallen (Rogaratinib (BAY1163877), Combination drug)

      Completed
      • Cancer
      • Rogaratinib (BAY1163877)
      • Combination drug
      • St. Gallen, Sankt Gallen, Switzerland
        Kantonsspital St. Gallen
      Mar 20, 2022